Holen Sie sich die Stockscreener-App
78.89
2.13%
-1.72
Handel nachbörslich:
78.89
Schlusskurs vom Vortag:
$80.61
Offen:
$79.76
24-Stunden-Volumen:
549.37K
Relative Volume:
0.88
Marktkapitalisierung:
$6.49B
Einnahmen:
$51.48M
Nettoeinkommen (Verlust:
$-315.00M
KGV:
-22.09
EPS:
-3.5708
Netto-Cashflow:
$-244.00M
1W Leistung:
-4.04%
1M Leistung:
-11.13%
6M Leistung:
+19.46%
1J Leistung:
+161.48%
1-Tages-Spanne:
$78.32
$81.15
1-Wochen-Bereich:
$76.87
$83.41
52-Wochen-Spanne:
$28.06
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
78.89 | 6.63B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Eagle Health Investments LP Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
CCORF Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $106 - Moomoo
Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN
Which Is a Better Investment, Kymera Therapeutics, Inc. or Nurix Therapeutics, Inc. Stock? - AAII
Kymera presents KT-621 atopic dermatitis trial data at conferences - Investing.com UK
Kymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical Progress - Yahoo Finance
T. Rowe Price reports 5.46M-share stake in Kymera (KYMR) - Stock Titan
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses - Investing News Network
Kymera presents KT-621 atopic dermatitis trial data at conferences By Investing.com - Investing.com Nigeria
Wellington group holds 3.89M shares in Kymera (KYMR) — 4.76% stake - Stock Titan
Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses - marketscreener.com
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses - GlobeNewswire Inc.
Kymera Therapeutics stock (US50153V1061): Featured in psoriasis pipeline report - AD HOC NEWS
Why (KYMR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Kymera Therapeutics stock (US50153V1061): Director sells $261K in shares amid strong Q1 revenue - AD HOC NEWS
Law firm investigates Kymera Therapeutics for possible breach of fiduciary duties by directors - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock By Investing.com - Investing.com Australia
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock - Investing.com
Kymera (KYMR) director Ridloff exercises options, sells 3,000 shares under 10b5-1 plan - Stock Titan
KYMR (KYMR) Form 144: 3,000-share sale; prior 10b5-1 sales disclosed - Stock Titan
Kymera Therapeutics stock (US50153V1061): Up after Q1 beat and new IBD data for KT-579 degrader cand - AD HOC NEWS
How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential - Yahoo Finance
State of New Jersey Common Pension Fund D Makes New $2.61 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
CCORF Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $106 - Moomoo
FMR LLC holds 14.3% of Kymera Therapeutics (NASDAQ: KYMR) in 13G/A - Stock Titan
Kymera Therapeutics to Participate in Upcoming May Investor Conferences - Investing News Network
Kymera’s IRF5 degrader shows potential in IBD treatment - BioWorld News
Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Vanguard Group Inc. Buys 845,922 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera lines up two May investor webcasts from Las Vegas and New York - Stock Titan
Canaccord Genuity initiates coverage of Kymera Therapeutics (KYMR) with buy recommendation - MSN
Kymera presents preclinical data for IBD drug candidate KT-579 By Investing.com - Investing.com South Africa
Kymera presents preclinical data for IBD drug candidate KT-579 - Investing.com UK
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week - Investing News Network
Equities Analysts Issue Forecasts for KYMR Q2 Earnings - MarketBeat
Oral bowel disease drug matched approved therapies in preclinical tests - Stock Titan
Kymera Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-05-04 - Seeking Alpha
Kymera Therapeutics Q1 2026 earnings preview - MSN
Kymera Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
H.C. Wainwright Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $134 - Moomoo
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):